Mo1878 – Lymphocyte Activation Gene (LAG)-3 on T Cells is a Potential Therapeutic Target in Ulcerative Colitis
Stephanie Slevin(John Radcliffe Hospital), Satish Keshav(John Radcliffe Hospital), Kate D. Lynch(Royal Adelaide Hospital), Naren Srinivasan(Age UK), Alessandra Geremia(John Radcliffe Hospital), Daniel J. Marks, Borgel Greenaway(John Radcliffe Hospital), Katherine Nevin(GlaxoSmithKline (United Kingdom)), Lai Mun Wang(John Radcliffe Hospital), Stephen Hughes(GlaxoSmithKline (United Kingdom)), Simon Travis(University of Oxford), Conor Lahiff(Beth Israel Deaconess Medical Center), C Arancibia(University of Oxford), Malcolm Tan(John Radcliffe Hospital), Ruth M. Tarzi(Hammersmith Hospital)
Cited by 0
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease
|The Journal of Experimental Medicine|2011|623
European evidence based consensus on the diagnosis and management of Crohn’s disease: current management
|Gut|2006|603
European evidence-based Consensus on the management of ulcerative colitis: Current management
|Journal of Crohn s and Colitis|2008|558
Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease
|Journal of Hepatology|2013|481